UA101362C2 - Protein tyrosine kinase activity inhibitors - Google Patents

Protein tyrosine kinase activity inhibitors

Info

Publication number
UA101362C2
UA101362C2 UAA201011785A UAA201011785A UA101362C2 UA 101362 C2 UA101362 C2 UA 101362C2 UA A201011785 A UAA201011785 A UA A201011785A UA A201011785 A UAA201011785 A UA A201011785A UA 101362 C2 UA101362 C2 UA 101362C2
Authority
UA
Ukraine
Prior art keywords
tyrosine kinase
kinase activity
protein tyrosine
activity inhibitors
compounds
Prior art date
Application number
UAA201011785A
Other languages
English (en)
Ukrainian (uk)
Inventor
Мишель Маннион
Стефан Раппель
Стефен Вильям Кларидж
Фредерик Годетте
Лиже Зан
Любомир ИСАКОВИЧ
Оскар Марио СААВЕДРА
Тесююки Уно
Масаши КИШИДА
Аркадий Вайсбург
Original Assignee
Метилген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Метилген Инк. filed Critical Метилген Инк.
Publication of UA101362C2 publication Critical patent/UA101362C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Это изобретение касается соединений, которые ингибируют активность протеинтирозинкиназ. В частности, изобретение касается соединений, которые ингибируют активность протеинтирозинкиназ рецепторов факторов роста, который приводит к ингибированию сигнализации рецепторов, например ингибирования сигнализации рецепторов VEGF.Изобретение также предлагает соединения, композиции и способы лечения болезней и состояний разрастания клеток и офтальмологических болезней, расстройств и состояний.
UAA201011785A 2008-03-05 2009-02-27 Protein tyrosine kinase activity inhibitors UA101362C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3400508P 2008-03-05 2008-03-05
PCT/CA2009/000228 WO2009109035A1 (en) 2008-03-05 2009-02-27 Inhibitors of protein tyrosine kinase activity

Publications (1)

Publication Number Publication Date
UA101362C2 true UA101362C2 (en) 2013-03-25

Family

ID=41055503

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA201011785A UA101362C2 (en) 2008-03-05 2009-02-27 Protein tyrosine kinase activity inhibitors
UAA201013462A UA100262C2 (ru) 2008-03-05 2009-02-27 Ингибиторы активности протеинтирозинкиназы

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA201013462A UA100262C2 (ru) 2008-03-05 2009-02-27 Ингибиторы активности протеинтирозинкиназы

Country Status (19)

Country Link
US (3) US8729268B2 (ru)
EP (2) EP2332536A1 (ru)
JP (2) JP2011513339A (ru)
KR (2) KR20100132068A (ru)
CN (2) CN102161663B (ru)
AR (2) AR070539A1 (ru)
AU (2) AU2009221583B2 (ru)
BR (2) BRPI0908573A2 (ru)
CA (2) CA2717816A1 (ru)
CO (1) CO6290684A2 (ru)
IL (2) IL207946A0 (ru)
MX (1) MX2010009729A (ru)
NZ (2) NZ589336A (ru)
RU (2) RU2533827C2 (ru)
SG (1) SG182146A1 (ru)
TW (2) TW200940549A (ru)
UA (2) UA101362C2 (ru)
WO (1) WO2009109035A1 (ru)
ZA (2) ZA201005868B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2717816A1 (en) * 2008-03-05 2009-09-11 Tetsuyuki Uno Inhibitors of protein tyrosine kinase activity
CN102498114A (zh) * 2009-09-03 2012-06-13 阿勒根公司 作为酪氨酸激酶调节剂的化合物
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
CN102947315A (zh) * 2010-04-16 2013-02-27 梅特希尔基因公司 蛋白酪氨酸激酶活性抑制剂
TWI492949B (zh) * 2010-06-09 2015-07-21 Abbvie Bahamas Ltd 結晶型激酶抑制劑
CA2802042A1 (en) * 2010-06-09 2011-12-15 Abbott Laboratories Crystalline forms of kinase inhibitors
TWI482770B (zh) * 2010-06-09 2015-05-01 Abbvie Bahamas Ltd 結晶型激酶抑制劑
SG187956A1 (en) * 2010-08-27 2013-03-28 Merck Patent Gmbh Furopyridine derivatives
CA2811479A1 (en) * 2010-09-17 2012-03-22 Purdue Pharma L.P. Pyridine compounds and the uses thereof
BRPI1004176A2 (pt) * 2010-10-25 2015-08-11 Univ Rio De Janeiro Compostos aril e/ou hetero aril uréias funcionalizados; processo de síntese desses composto; composição farmacêutica contendo tais compostos e usos
WO2013044360A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
WO2013044362A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Selected inhibitors of protein tyrosine kinase activity
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
CA2970155A1 (en) * 2014-12-09 2016-06-16 Abbvie Inc. Bcl-xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR112020015581A2 (pt) 2018-01-31 2021-02-02 Deciphera Pharmaceuticals, Llc terapia de combinação para o tratamento de tumores estromais gastrointestinais
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
EP4084779A1 (en) 2019-12-30 2022-11-09 Deciphera Pharmaceuticals, LLC Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
TW202342426A (zh) * 2022-02-15 2023-11-01 大陸商百濟神州（蘇州）生物科技有限公司 N-[(6-溴吡啶-3-基)甲基]-2-甲氧基乙烷-1-胺鹽及其製備方法
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7000A (en) * 1850-01-08 Smut-machine
US7019A (en) * 1850-01-15 Improvement in obstetrical supporters
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
WO1999024440A1 (en) 1997-11-11 1999-05-20 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
BR9910864A (pt) 1998-06-04 2002-02-05 Abbott Lab Compostos anti-inflamatórios para inibição de aderência celular
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
JP2003535867A (ja) 2000-06-06 2003-12-02 ファイザー プロダクツ インコーポレイテッド 抗癌剤として有用なチオフェン誘導体
US20020004511A1 (en) 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
EP1777218B1 (en) * 2000-10-20 2008-12-31 Eisai R&D Management Co., Ltd. Process for the preparation of 4-phenoxy quinoline derivatives
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000194A2 (en) 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
EP1483268A2 (en) 2002-03-01 2004-12-08 Pfizer Inc. Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
US20030199525A1 (en) 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
US20050065171A1 (en) 2003-06-25 2005-03-24 Shakespeare William C. Substituted purine derivatives
EP1660504B1 (en) 2003-08-29 2008-10-29 Pfizer Inc. Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
WO2005052872A1 (en) 2003-11-21 2005-06-09 Facil, Llc Financial transaction system and method
EP1711495A2 (en) 2004-01-23 2006-10-18 Amgen Inc. Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
WO2005121125A1 (en) * 2004-06-09 2005-12-22 Pfizer Inc. Ether-linked heteroaryl compounds
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
AU2005270068B2 (en) 2004-07-02 2012-04-19 Exelixis, Inc. C-Met modulators and method of use
CA2573999A1 (en) 2004-07-16 2006-04-06 Sunesis Pharmaceuticals, Inc. Thienopyrimidines useful as aurora kinase inhibitors
WO2006010264A1 (en) 2004-07-30 2006-02-02 Methylgene, Inc. Inhibitors of vegf receptor and hgf receptor signaling
EP1827434B1 (en) 2004-11-30 2014-01-15 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
CA2603748A1 (en) 2005-04-06 2006-10-12 Exelixis, Inc. C-met modulators and methods of use
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
KR101378716B1 (ko) * 2005-05-20 2014-04-10 메틸진 인코포레이티드 Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달의 억제제
DK1904504T3 (da) 2005-05-20 2014-06-23 Methylgene Inc Inhibitorer af vegf-receptor- og hgf-receptorsignalering
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
EP1989211A2 (en) * 2006-01-30 2008-11-12 Array Biopharma, Inc. Heterobicyclic thiophene compounds for the treatment of cancer
US20080064718A1 (en) 2006-03-22 2008-03-13 Saavedra Oscar M Inhibitors of protein tyrosine kinase activity
US7298968B1 (en) * 2007-01-05 2007-11-20 Rheem Manufacturing Company Pumpless combination instantaneous/storage water heater system
CN101932586A (zh) * 2007-08-29 2010-12-29 梅赛尔基因股份有限公司 蛋白酪氨酸激酶活性的抑制
CA2717816A1 (en) * 2008-03-05 2009-09-11 Tetsuyuki Uno Inhibitors of protein tyrosine kinase activity
CN102947315A (zh) * 2010-04-16 2013-02-27 梅特希尔基因公司 蛋白酪氨酸激酶活性抑制剂

Also Published As

Publication number Publication date
JP5661485B2 (ja) 2015-01-28
CA2717816A1 (en) 2009-09-11
AU2010246540B2 (en) 2013-02-28
JP2011513339A (ja) 2011-04-28
CN102015723B (zh) 2014-07-30
AR070539A1 (es) 2010-04-14
NZ589336A (en) 2011-12-22
BRPI0923670A2 (pt) 2013-07-30
NZ588355A (en) 2012-03-30
WO2009109035A1 (en) 2009-09-11
IL208882A0 (en) 2011-07-31
TW201113288A (en) 2011-04-16
AU2009221583A2 (en) 2011-02-03
US8729268B2 (en) 2014-05-20
RU2010145459A (ru) 2012-05-20
KR20100137495A (ko) 2010-12-30
UA100262C2 (ru) 2012-12-10
EP2262815A4 (en) 2012-04-11
US20110077240A1 (en) 2011-03-31
ZA201005868B (en) 2011-08-31
MX2010009729A (es) 2010-12-21
RU2533827C2 (ru) 2014-11-20
CA2763168A1 (en) 2009-09-11
CO6290684A2 (es) 2011-06-20
SG182146A1 (en) 2012-07-30
EP2262815A1 (en) 2010-12-22
US8759522B2 (en) 2014-06-24
AU2010246540A1 (en) 2010-12-23
CN102015723A (zh) 2011-04-13
US20140179632A1 (en) 2014-06-26
TW200940549A (en) 2009-10-01
CN102161663A (zh) 2011-08-24
CN102161663B (zh) 2014-03-19
RU2010140668A (ru) 2012-04-10
TWI438205B (zh) 2014-05-21
AU2009221583A1 (en) 2009-09-11
KR20100132068A (ko) 2010-12-16
RU2498988C2 (ru) 2013-11-20
JP2011105735A (ja) 2011-06-02
AU2009221583B2 (en) 2013-06-20
EP2332536A1 (en) 2011-06-15
US20110098293A1 (en) 2011-04-28
BRPI0908573A2 (pt) 2012-12-25
AR079208A2 (es) 2012-01-04
IL207946A0 (en) 2010-12-30
ZA201007517B (en) 2012-01-25

Similar Documents

Publication Publication Date Title
UA101362C2 (en) Protein tyrosine kinase activity inhibitors
WO2008035209A3 (en) Quinoline and quinazoline derivatives as inhibitors of protein tyrosine kinase activity
MY157319A (en) Inhibitors of protein tyrosine kinase activity
WO2007149427A3 (en) Tyrosine kinase inhibitors
PH12020551208A1 (en) Compounds for the treatment of kinase-dependent disorders
SI1896421T1 (sl) Benzocikloheptapiridini kot inhibitorji receptorjev tirozin kinaze met
MX2007014616A (es) Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos.
WO2010005876A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
NO20090608L (no) Tyrosinkinaseinhibitorer
JOP20120246B1 (ar) مركبات و تركيبات كمثبطات كيناز c-Kit
MY165728A (en) Selective glycosidase inhibitors and uses thereof
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
MX339937B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
JO3002B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
EP3715457A3 (en) Modulation of prekallikrein (pkk) expression
GB2460597A (en) N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
MX2011008602A (es) Metodos de tratamiento de condiciones relacionadas con el cabello.
WO2006086358A3 (en) Mitotic kinesin inhibitors
TW200738638A (en) Tyrosine kinase inhibitors
MX2010007669A (es) Metodos para inhibir la angiogenesis utilizando antagonistas de egfl8.
WO2014110198A3 (en) Therapeutic indications of kinase inhibitors